Risk of Infection Associated with Ibrutinib in Patients with B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Conflicting reports exist on risk of infection with ibrutinib, We conducted a systematic review and meta-analysis of randomized controlled trials to estimate the relative risk, Ibrutinib use was associated with a statistically significant increased risk of infection in patients with B-cell malignancies, Patients on ibrutinib should be vigilantly monitored for development of infections

Source: Clinical Lymphoma, Myeloma and Leukemia - October 12, 2019 Category: Hematology Authors: Somedeb Ball, Avash Das, Wasawat Vutthikraivit, Peggy J. Edwards, Fred Hardwicke, Nicholas J. Short, Gautam Borthakur, Abhishek Maiti. Tags: Original Study Source Type: research